Under the terms of the agreement, Avid will support Oragenics in the development of Terra CoV-2, Oragenics' vaccine candidate that targets the spike protein of SARS-CoV-2. Avid will provide Oragenics with analytical method development, process development, and drug substance manufacturing services.

The companies will first conduct an initial project phase that includes analytical method feasibility and quantification activities. They then plan to advance upstream and downstream process development and manufacture Terra CoV-2 at Avid's Myford facility in Tustin, CA.

Oragenics anticipates the partnership will help the company meet its goal of conducting human clinical trials of the Terra CoV-2 vaccine candidate by early 2021.

Adaptive Phage gets $10M to develop COVID-19 vaccine
Adaptive Phage Therapeutics has been awarded $9.8 million by the U.S. Department of Defense to develop multiple high-priority bacteriophage-based...

Early trials show potential of Pfizer COVID-19 vaccine
Pharmaceutical giant Pfizer is making progress on BNT162b1, a COVID-19 vaccine candidate that is undergoing development and for which the U.S. government...

Sharing is caring: Why COVID-19 vaccine manufacturers must collaborate
Sharing knowledge between competitors will be key for establishing the manufacturing capacity needed to produce billions of COVID-19 vaccines in coming...

U.S. to pay $1.5B for Moderna's COVID-19 vaccine
The U.S. government awarded a maximum $1.525 billion contract to Moderna to secure 100 million doses of its messenger RNA COVID-19 vaccine.

Oragenics identifies SARS-CoV-2 neutralizing antibodies
A stabilized prefusion spike protein licensed by Oragenics has generated neutralizing antibodies in mice during immunization against SARS-CoV-2, according...